UniProtKB/Swiss-Prot P04637: Variant p.Gly262Ser

Cellular tumor antigen p53
Gene: TP53
Feedback?

Variant information Variant position:

262 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Serine (S) at position 262 (G262S, p.Gly262Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In sporadic cancers; somatic mutation. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs200579969 [ dbSNP | Ensembl ]

Sequence information Variant position:

262 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

393 The length of the canonical sequence.
Location on the sequence:

CMGGMNRRPILTIITLEDSS G NLLGRNSFEVRVCACPGRDR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         CMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDR

                              CMGGMNRRPILTIITLEDSSGNVLGRNSFEVRVCACPGRDR

Rhesus macaque                CMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDR

Mouse                         CMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDR

Rat                           CMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDR

Pig                           CMGGMNRRPILTIITLEDASGNLLGRNSFEVRVCACPGRDR

Bovine                        CMGGMNRRPILTIITLEDSCGNLLGRNSFEVRVCACPGRDR

Rabbit                        CMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDR

Sheep                         CMGGMNRRPILTIITLEDSRGNLLGRSSFEVRVCACPGRDR

Cat                           CMGGMNRRPIITIITLEDSNGKLLGRNSFEVRVCACPGRDR

Chicken                       CMGGMNRRPILTILTLEGPGGQLLGRRCFEVRVCACPGRDR

Xenopus laevis                CMGGMNRRPILTIITLETPQGLLLGRRCFEVRVCACPGRDR

Zebrafish                     CMGGMNRRPILTIITLETQEGQLLGRRSFEVRVCACPGRDR

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 393	Cellular tumor antigen p53
DNA binding	102 – 292
Region	1 – 320	Interaction with CCAR2
Region	100 – 370	Interaction with HIPK1
Region	100 – 300	Required for interaction with ZNF385A
Region	116 – 292	Interaction with AXIN1
Region	256 – 294	Interaction with E4F1
Binding site	242 – 242
Modified residue	269 – 269	Phosphoserine; by AURKB
Mutagenesis	248 – 248	R -> S. Does not induce SNAI1 degradation.
Mutagenesis	269 – 269	S -> A. Abolishes phosphorylation.
Mutagenesis	269 – 269	S -> E. Inhibits strongly its transcriptional activity.
Beta strand	260 – 262

Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.